Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

Full Text:

Abstract

Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn’t shown. Research was conducted from a position of the state health system by means of mathematical modeling. Markov modeling and the sensitivity analysis were used. For primary patients who aren’t candidates for transplantation the following regimes of treatment were compared of: bendamustine + prednisone; melphalan + prednisone; bortezomibe + dexamethasone. The results show that the use of bendamustine in the first line of therapy of a multiple myeloma for elderly patients with the phenomena of a polyneuropathy is economically expedient from the point of view of a ratio of cost and efficiency.

About the Authors

A. S. Kolbin
First Pavlov State Medical University of St. Peterburg; Saint Petersburg State University, St. Petersburg, Russia
Russian Federation


I. A. Vilum
National Medical and Surgical Center of the N.I. Pirogov, St. Peterburg
Russian Federation


Yu. E. Balykina
Saint Petersburg State University, St. Petersburg, Russia
Russian Federation


M. A. Proskurin
Saint Petersburg State University, St. Petersburg, Russia
Russian Federation


References

1. Abdulkadyrov K.M. clinical hematology [Klinicheskaya gematologiya]. St. Petersburg. 2006; 447 s.

2. Avksent'eva M.A., Gerasimov B.V., Sura M.V. Clinical and economic analysis (evaluation, selection of medical technology and quality management of medical care). Ed. Vorobyov PA [Klinikoekonomicheskii analiz (otsenka, vybor meditsinskikh tekhnologii i upravleniya kachestvom meditsinskoi pomoshchi). Pod red. Vorob'eva] P.A. Moscow. 2004; 404 s.

3. Andreeva N.E., Balakireva T.V. Paroproteinemicheskie gemablostozy: Multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease [Paroproteinemicheskie gemablostozy: Mnozhestvennaya mieloma, makroglobulinemiya Val'denstrema, bolezni tyazhelykh tsepei]. Tver'. 2003; 88 s.

4. Belousov Yu.B. Planning and conduct of clinical trials of medicinal products [Planirovanie i provedenie klinicheskikh issledovanii lekar-stvennykh sredstv]. Moscow. 2000; 579 s.

5. Belousov D.Yu., Afanas'eva E.V., Efremova E.A. Kachestvennaya klinicheskaya praktika. 2013; 3: 15-20.

6. Diagnosis and treatment of multiple myeloma. Recommendations of the British Forum for multiple myeloma and Scandinavian Study Group myeloma [Diagnostika i lechenie mnozhestvennoi mielomy. Rekomendatsii Britanskogo foruma po mnozhestvennoi mielome i Skandinavskoi issledovatel'skoi gruppy po mnozhestvennoi mielome]. 2005.

7. National clinical guidelines for the diagnosis and treatment set myeloma. Hematology and Blood Transfusion. Application number 3 [Natsional'nye klinicheskie rekomendatsii po diagnostike i lecheniyu mnozhe-stvennoi mielomy. Gematologiya i transfuziologiya. Prilozhenie № 3]. 2014 (1).

8. On approval of the industry standard «clinical research ekonomieskie. General»: the order number 163 of the Ministry of Health of the Russian Federation dated 27.05.2011.

9. Government Decree of October 22, 2012 № 1074 «On the program of state guarantees of free citizens providing medical care for 2013 and the planning period of 2014 and 2015».

10. Decree of the Government of St. Petersburg from 26.02.2010 № 176 «On the establishment of trade price premiums for drugs and medical products».

11. Professional pharmaceutical portal «FARMindeks» [Professional'nyi farmatsevticheskii portal «FARMindeks»]. http://www.pharmindex.ru/.

12. The Order of the Ministry of Health of 24.12.2012, № 1458n «On approval of the standard of primary health care in refractory and recurrent C. for SRI multiple myeloma and other plasma cell malignant neoplasms».

13. Regulation of the Committee on Economic Policy and Strategic Planning of St. Petersburg of 17.07.2013 N 103-p «On approval of the financial cost of providing public services (works) for specialized medical care in geriatric institutions (offices, classrooms) care provided in hospices (offices, hospices), and medical care provided in nursing departments, autonomous and state budgetary institutions».

14. Rudakova A.V. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2011; 4 (3): 29-33.

15. Rudakova A.V. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2011; 4 (3): 23-28.

16. Site of the State register of medicines. http://grls.rosminzdrav.ru.

17. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 2009; 27: 1492-501.

18. http://www.spboms.ru/kiop/main?page_id=338.

19. http://www.pokrov.spb.ru/stoimostq-uslug.html.

20. Leoni L. et al. Clin. Cancer. Res. 2008; 309 (14): 309-317.

21. Moreau P., Pylypenko H., Grosicki S. et al. Subcutaneous versus intravenous admin-istration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet. Oncol. 2011; 12: 431-40.

22. Mateos M.V., Hernandenz J.M., Hernandenz M.T. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multcenter phase 1/2 study. Blood. 2006; 108: 2165-2172.

23. Palumbo A. et al. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Im-proved Survival. Journal of Clinical Oncology. 2014 January 21. [EPub Ahead of Print].

24. Ponisch W. et al., Treatment of bendamustine and prednisone in patients with newly di-agnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of He-matology and Oncology (OSHO). J. Cancer. Res. Clin. Oncol. 2006. 132 (4): 205-12.

25. Rummel M.J., Al-Batran S., Kim S.Z. et al: Ribomustin plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23: 3383-3389.

26. San Miguel J.F., Schalg R., Khuageva N. et al. MMY-3002: A phase-3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood. 2007; 110: 31a (abstract 76).

27. URL: www.medlux.ru.

28. Walley T., Haycox A., Boland A. Pharmacoeconomics. Elsevier Health Sciences. 2004; 216 s.

29. Weinstein M.C., O'Brien B., Hornberger J. et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies.Value Health. 2003; 6 (1): 9-17.


For citation:


Kolbin A.S., Vilum I.A., Balykina Y.E., Proskurin M.A. PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(2):6-12. (In Russ.)

Views: 354


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)